Results 11 to 20 of about 677,925 (163)
WEE1 inhibition sensitizes osteosarcoma to radiotherapy [PDF]
BMC Cancer, 2011 Background The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an ...
Helder Marco N +6 more
doaj +3 more sources
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib [PDF]
Scientific Reports, 2018 AbstractNon-Small-Cell Lung Cancer (NSCLC) is a poorly chemosensitive tumor and targeted therapies are only used for about 15% of patients where a specific driving and druggable lesion is observed (EGFR, ALK, ROS). KRAS is one of the most frequently mutated genes in NSCLC and patients harboring these mutations do not benefit from specific treatments ...
Caiola E. +7 more
core +5 more sources
Targeting WEE1 Kinase in Gynecological Malignancies [PDF]
Drug Design, Development and TherapyWenhao Zhang,1,2 Qingli Li,1,2,* Rutie Yin1,2,* 1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Key Laboratory of Birth Defects and Related Diseases of ...
Zhang W, Li Q, Yin R
doaj +1 more source
Cell Death and DiseaseThe clinical effect of KRAS G12C inhibitors (G12Ci) as monotherapy is poor, prompting the development of combination treatment strategies. Here, we demonstrate that the WEE1 kinase inhibitor (WEE1i), Adavosertib, can sensitize the effect of G12Ci through
Chao Zhou +8 more
doaj +2 more sources
WEE1-inhibition and hypoxia : The impact of hypoxia and reoxygenation on the S-phase effects of the WEE1-inhibitor MK-1775 [PDF]
, 2013 The WEE1-inhibitor MK-1775 is currently in clinical trials as an anti-cancer drug. In response to DNA damage, human cells activate cell cycle checkpoints to temporarily halt cell cycle progression, and this helps facilitating DNA repair and is important to preserve genomic stability.
Hauge, Sissel
openaire +2 more sources
, 2022 Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ...
Marta Palafox (15051587) +39 more
core +2 more sources
WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
, 2021 International audienceThe WEE1 G2 checkpoint kinase acts as a negative cell cycle regulator for entry into mitosis (G2-to-M transition). This comment extends a recent Advanced Science paper by reporting higher WEE1-dependency of triple negative breast ...
Nonneville, Alexandre +10 more
core +1 more source
, 2022 Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ...
Marta Palafox (15051587) +39 more
core +2 more sources
Cdk1-Dependent Regulation of the Mitotic Inhibitor Wee1 [PDF]
Cell, 2005 The Wee1 kinase phosphorylates and inhibits cyclin-dependent kinase 1 (Cdk1), thereby delaying entry into mitosis until appropriate conditions have been met. An understanding of the mechanisms that regulate Wee1 should provide new insight into how cells make the decision to enter mitosis.
Harvey, Stacy L. +4 more
openaire +2 more sources
Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations [PDF]
Frontiers in Medicine, 2021 p53 is among the most frequently mutated tumor suppressor genes given its prevalence in >50% of all human cancers. One critical tumor suppression function of p53 is to regulate transcription of downstream genes and maintain genomic stability by inducing the G1/S checkpoint in response to DNA damage.
Xiangbing Meng +7 more
openaire +3 more sources